Cargando…

Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review

Immune checkpoint inhibitors (ICIs) have substantially changed the treatment of a variety of malignant tumors. With the increasing of their usage, the unique immune-mediated toxicity profile of ICIs has become apparent. We report a case of esophageal squamous cell carcinoma in a patient who received...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Jing, Li, Dan, Yang, Peidan, Xu, Kunyan, Wang, Yingnan, Li, Qian, Liu, Jiang, Du, Wenli, Zhang, Fengbin, Feng, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761813/
https://www.ncbi.nlm.nih.gov/pubmed/35047395
http://dx.doi.org/10.3389/fonc.2021.778185
_version_ 1784633615579086848
author Bai, Jing
Li, Dan
Yang, Peidan
Xu, Kunyan
Wang, Yingnan
Li, Qian
Liu, Jiang
Du, Wenli
Zhang, Fengbin
Feng, Rui
author_facet Bai, Jing
Li, Dan
Yang, Peidan
Xu, Kunyan
Wang, Yingnan
Li, Qian
Liu, Jiang
Du, Wenli
Zhang, Fengbin
Feng, Rui
author_sort Bai, Jing
collection PubMed
description Immune checkpoint inhibitors (ICIs) have substantially changed the treatment of a variety of malignant tumors. With the increasing of their usage, the unique immune-mediated toxicity profile of ICIs has become apparent. We report a case of esophageal squamous cell carcinoma in a patient who received anti-programmed cell death protein 1 (PD-1) (camrelizumab) therapy and the occurrence of sequential immune-related adverse events (irAEs). Although many irAEs have been reported, severe myositis caused by camrelizumab with simultaneous involvement of multiple organs, including the myocardium, respiratory muscles, and skeletal muscles, has rarely been described in literature. This 69-year-old male patient developed a grade 4 camrelizumab-induced adverse reaction according to the Common Terminology Criteria for Adverse Events (CTCAE) and was successfully treated with methylprednisolone and immunoglobulins. The early identification of irAEs, immediate discontinuation of immunotherapy, use of steroids and/or immunosuppressants, and adjuvant supportive treatment are critical to the clinical prognosis of patients. It should be aware that autoimmune complications can occur even when ICI treatment is ceased.
format Online
Article
Text
id pubmed-8761813
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87618132022-01-18 Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review Bai, Jing Li, Dan Yang, Peidan Xu, Kunyan Wang, Yingnan Li, Qian Liu, Jiang Du, Wenli Zhang, Fengbin Feng, Rui Front Oncol Oncology Immune checkpoint inhibitors (ICIs) have substantially changed the treatment of a variety of malignant tumors. With the increasing of their usage, the unique immune-mediated toxicity profile of ICIs has become apparent. We report a case of esophageal squamous cell carcinoma in a patient who received anti-programmed cell death protein 1 (PD-1) (camrelizumab) therapy and the occurrence of sequential immune-related adverse events (irAEs). Although many irAEs have been reported, severe myositis caused by camrelizumab with simultaneous involvement of multiple organs, including the myocardium, respiratory muscles, and skeletal muscles, has rarely been described in literature. This 69-year-old male patient developed a grade 4 camrelizumab-induced adverse reaction according to the Common Terminology Criteria for Adverse Events (CTCAE) and was successfully treated with methylprednisolone and immunoglobulins. The early identification of irAEs, immediate discontinuation of immunotherapy, use of steroids and/or immunosuppressants, and adjuvant supportive treatment are critical to the clinical prognosis of patients. It should be aware that autoimmune complications can occur even when ICI treatment is ceased. Frontiers Media S.A. 2022-01-03 /pmc/articles/PMC8761813/ /pubmed/35047395 http://dx.doi.org/10.3389/fonc.2021.778185 Text en Copyright © 2022 Bai, Li, Yang, Xu, Wang, Li, Liu, Du, Zhang and Feng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Bai, Jing
Li, Dan
Yang, Peidan
Xu, Kunyan
Wang, Yingnan
Li, Qian
Liu, Jiang
Du, Wenli
Zhang, Fengbin
Feng, Rui
Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review
title Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review
title_full Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review
title_fullStr Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review
title_full_unstemmed Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review
title_short Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review
title_sort camrelizumab-related myocarditis and myositis with myasthenia gravis: a case report and literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761813/
https://www.ncbi.nlm.nih.gov/pubmed/35047395
http://dx.doi.org/10.3389/fonc.2021.778185
work_keys_str_mv AT baijing camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview
AT lidan camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview
AT yangpeidan camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview
AT xukunyan camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview
AT wangyingnan camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview
AT liqian camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview
AT liujiang camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview
AT duwenli camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview
AT zhangfengbin camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview
AT fengrui camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview